WO2009049820A3 - Amorphe formulierung - Google Patents

Amorphe formulierung Download PDF

Info

Publication number
WO2009049820A3
WO2009049820A3 PCT/EP2008/008533 EP2008008533W WO2009049820A3 WO 2009049820 A3 WO2009049820 A3 WO 2009049820A3 EP 2008008533 W EP2008008533 W EP 2008008533W WO 2009049820 A3 WO2009049820 A3 WO 2009049820A3
Authority
WO
WIPO (PCT)
Prior art keywords
amorphous formulation
amorphous
formulation
cellulose
substance
Prior art date
Application number
PCT/EP2008/008533
Other languages
English (en)
French (fr)
Other versions
WO2009049820A2 (de
Inventor
Stephan Michael Meier
Anja Ehrig
Original Assignee
Bayer Schering Pharma Ag
Stephan Michael Meier
Anja Ehrig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Stephan Michael Meier, Anja Ehrig filed Critical Bayer Schering Pharma Ag
Publication of WO2009049820A2 publication Critical patent/WO2009049820A2/de
Publication of WO2009049820A3 publication Critical patent/WO2009049820A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose
    • C08L1/04—Oxycellulose; Hydrocellulose, e.g. microcrystalline cellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Die Erfindung betrifft eine amorphe Formulierung mindestens einer bei Raumtemperatur festen Substanz, enthaltend Cellulose und/oder Cellulosederivate und gegebenenfalls mindestens eine oberflächenaktive Substanz, sowie ein Verfahren zu deren Herstellung.
PCT/EP2008/008533 2007-10-11 2008-10-09 Amorphe formulierung WO2009049820A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007048705.5 2007-10-11
DE200710048705 DE102007048705A1 (de) 2007-10-11 2007-10-11 Amorphe Formulierung

Publications (2)

Publication Number Publication Date
WO2009049820A2 WO2009049820A2 (de) 2009-04-23
WO2009049820A3 true WO2009049820A3 (de) 2009-06-11

Family

ID=40429982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008533 WO2009049820A2 (de) 2007-10-11 2008-10-09 Amorphe formulierung

Country Status (2)

Country Link
DE (1) DE102007048705A1 (de)
WO (1) WO2009049820A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2442799T (lt) 2009-06-18 2016-12-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Kieta farmacinė kompozicija, apimanti rivaroksabaną
EP2485715A1 (de) 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmazeutische zusammensetzungen mit rivaroxaban
EP2308472A1 (de) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmazeutische Zusammensetzungen, die Rivaroxaban umfassen
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
EP3796915A4 (de) 2018-11-16 2022-01-26 Santa Farma Ilaç Sanayi A.S. Orale formulierungen enthaltend rivaroxaban

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740934A1 (de) * 1995-05-02 1996-11-06 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
WO1996036318A2 (en) * 1995-05-19 1996-11-21 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov,D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
WO2001017546A1 (en) * 1999-09-09 2001-03-15 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6458745B1 (en) * 1996-10-11 2002-10-01 Basf Aktiengesellschaft Solid phytosanitary agent
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
WO2003039249A2 (en) * 2001-11-07 2003-05-15 Basf Aktiengesellschaft Nanoparticles comprising a crop protection agent
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119383A1 (de) 1981-05-15 1982-12-02 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
IT1284604B1 (it) 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US20050163842A1 (en) 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740934A1 (de) * 1995-05-02 1996-11-06 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
WO1996036318A2 (en) * 1995-05-19 1996-11-21 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov,D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US6458745B1 (en) * 1996-10-11 2002-10-01 Basf Aktiengesellschaft Solid phytosanitary agent
WO2001017546A1 (en) * 1999-09-09 2001-03-15 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
WO2003039249A2 (en) * 2001-11-07 2003-05-15 Basf Aktiengesellschaft Nanoparticles comprising a crop protection agent
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung

Also Published As

Publication number Publication date
DE102007048705A1 (de) 2009-04-16
WO2009049820A2 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2009145456A3 (ko) 헤테로사이클 유도체
WO2007093627A3 (de) Biozide zusammensetzung
WO2009036281A3 (en) Bortezomib and process for producing same
WO2009061740A3 (en) Process of producing ethanol using cellulose with enzymes generated through solid state culture
WO2008131062A3 (en) Process for preparing capecitabine
WO2008017346A3 (de) Ascorbinsäurederivate, verwendung zur funktionalisierung von matrices
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
WO2008058118A3 (en) Preparation of montelukast and its salts
WO2007115210A3 (en) Non-starchy rice bran polysaccharides
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2009037354A3 (en) Polysaccharide derived materials
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2008111096A3 (en) Novel prodrugs
WO2009049820A3 (de) Amorphe formulierung
EP2460420A4 (de) Verfahren zur herstellung von tabakblättern, verfahren zur herstellung von zigaretten mit den tabakblättern und zigarette
WO2007098273A3 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010039885A3 (en) Crystalline forms of dexlansoprazole
WO2008094617A3 (en) Crystalline forms of deferasirox
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
MX2009006479A (es) Derivados de hemicelulosa y estructuras que los emplean.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802843

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802843

Country of ref document: EP

Kind code of ref document: A2